Kinetics of versican-expressing macrophages in bone marrow after cord blood stem cell transplantation for treatment of acute myelogenous leukaemia

Miho Senda,1,2 Ryuichi Fukuyama,3 Tetsuro Nagasaka2

ABSTRACT

Aims To determine versican-producing cells in normocellular bone marrow and to evaluate chronological alteration in the number of versican-producing macrophages in bone marrow of patients with acute myelogenous leukaemia (AML) after cord blood stem cell transplantation (CBSCT) to gain insight in the significance of versican in recovery of haematopoiesis.

Methods We enrolled seven age-matched unrelated patients with normocellular bone marrow for determining versican-producing cells in bone marrow, CBSCT-treated patients with AML, 18 with fine and other four with poor engraftment, for determining chronological alteration of versican-expressing and CD68-expressing cells in transplanted bone marrow in reference to the total cells. Clot samples of patients with AML were collected from the +16 to +55 day after transplantation and separated into four groups. We included an AML case whose specimen was obtained on the +9 day. Cells positive in immunohistochemistry using antibodies to versican and CD68 were counted to obtain the mean±SD in a unit area of the bone marrow, plotted chronologically and compared with the numbers from the age-matched normocellular group.

Results We determined by a double immunohistochemistry that the versican-expressing cells in bone marrow are macrophages. The time-course curve demonstrated an inverse relationship between the versican-positive macrophages and the total cells in the transplanted bone marrow for over 55 days. In bone marrow of poor engraftment cases, versican-positive macrophages appeared to be decreased in comparison with age-matched and sampling day-matched patients.

Conclusions These results suggest that versican and/or versican-expressing macrophages positively contribute to bone marrow regeneration of patients with AML after CBSCT.

INTRODUCTION

Versican/PG-M is a type of large chondroitin sulfate proteoglycan belonging to the aggregan family, and plays important roles in cell adhesion, migration and differentiation as a molecule of extracellular matrix (ECM).1–4 Versican is first identified in culture medium of fibroblasts and its wide-range distribution is subsequently revealed in the smooth muscle cells,5 cartilage,6 skin7 and blood vessels.10 Versican is also expressed at the ECM of malignant tumors11 12 and developing embryos.10 13

The main cell type that produces versican in inflammatory lesions has been revealed to be macrophages.1 Many other reports also demonstrated that macrophages express versican and that it is overexpressed when they are activated by granulocyte-macrophage-colony-stimulating factor (GM-CSF),14 lipopolysaccharide15 and hypoxia.16 At ECM, it binds to hyaluronan and other ECM molecules such as fibronectin4 17 and several chemokines,18 19 thereby influencing leucocyte function.

Versican reportedly exists in the long-term culture of mouse bone marrow (BM) cells20 and in the ECM of BM cells after chemotherapy.21 Moreover, Oguri et al22 detected a large amount of proteoglycan with chondroitin 6-sulfate in rabbit BM tissues. Although versican in BM has not been analysed biochemically, proteoglycans at the ECM have been known as binding partners for humoral factors that activate haematopoietic progenitors.23 24 These reports support the hypothesis that versican may play an important role in the haematopoiesis of BM. Localisation of versican in BM tissue has been analysed immunohistochemically, yet the cells that produce versican in this tissue were not delineated.

Transplantation of cord blood (CB), BM and peripheral blood (PB) stem cells (SCs) has been performed for treatment of haematopoietic diseases such as leukaemia. Down these lines, Nagasaka et al21 showed that the versican level is increased in BM of patients who have undergone chemotherapy. Therefore, it is likely that versican in BM may positively influence haematopoiesis in tissue after transplantation. To date, no study has been conducted to elucidate versican’s overexpression and role in transplanted BM.

The purpose of this study is to identify versican-producing cells in normal BM and to shed light on the significance of versican in transplanted BM.

PATIENTS AND METHODS

Patients

To address the possible significance of versican in BM regeneration, we enrolled 18 patients with acute myelogenous leukaemia (AML) who underwent cord blood stem cell transplantation (CBSCT). As we obtained clot specimens from an AML case 3 times and from 3 AML cases 2 times, the total number of samples in the assessment was 23. Three different stem cell transplantation (SCT) procedures have been performed at our hospital, namely, CBSCT, BMSCT and PBSCT. CBSCT is our current standard procedure because the graft versus host defence is less pronounced with it, and only a part of human leucocytic antigens needs to be matched.24 25 Therefore, we confined our analysis to CBSCT-treated patients. Our preparative regimen for CBSCT was based on previous reports,
which was recently summarised by Arai et al.\(^2\) and was shown in table 1.

BM clot was collected from the +16 to +55 day after transplantation for routine cytological and pathological evaluation of engraftment. We separated patients into four groups based on the duration after transplantation as follows: 16–25, 26–35, 36–45 and 46–55 days. We included a case, whose specimen was obtained at the +9 day to examine a cause of his high fever, because it likely shows a possible tendency of the number of versican-positive/CD68-positive macrophages in the early phase of the recovery. The breakdown of these samples is shown in table 2.

According to the record, no patients experienced recurrence. We identified four other patients with AML who exhibited severe hypocellularity in BM about 3–5 weeks after CBSCT, likely showing engraftment failure. We analysed this age-matched poor engraftment group in the same way and compared with the corresponding 16–25 and 26–33 groups (namely, age-matched and sampling day-matched control). To determine versican-expressing cells in BM, we selected seven patients whose BM was isolated for diagnostic purpose and was normocellular, and then clinicopathologically diagnosed not to have haematological and other significant diseases. We named this an age-matched normocellular group (table 1) and the numbers of the total cells, and versican-positive and CD68-positive cells were used as a baseline for the kinetics assessment. Informed consent was obtained from each patient and the protocol was approved by the ethical committee of Nagoya University.

### Immunohistochemistry

All samples used in this study were formalin-fixed and paraffin-embedded. Several 4 μm-thick sections were cut from the paraffin blocks, and one was stained with H&E for diagnostic purposes. In immunohistochemistry (IHC), antigen-bound antibodies were visualised using a kit (Bond Polymer Refine Detection, Leica Biosystems Newcastle, UK), and brown colour was developed with diaminobenzidine (DAB).

Since versican-expressing cells were found likely to be macrophages, we performed double IHC using antibodies to versican (Abcam, Cambridge, UK) and to CD68 (PG-M1; Dako, Glostrup, Denmark). We employed this CD68 antibody because it likely shows a possible tendency of the number of versican-positive/CD68-positive macrophages in the early phase of the recovery. In immunohistochemistry (IHC), antigen-bound antibodies were visualised using a kit (Bond Polymer Refine Detection, Leica Biosystems Newcastle, UK), and brown colour was developed with diaminobenzidine (DAB).

Since versican-expressing cells were found likely to be macrophages, we performed double IHC using antibodies to versican (Abcam, Cambridge, UK) and to CD68 (PG-M1; Dako, Glostrup, Denmark). We employed this CD68 antibody because it was used to label all macrophages in BM.\(^2\) With this technique, after versican-bound antibody was visualised with a brown colour with DAB, anti-CD68 antibody was reacted to the tissue section, and coloured red using the Bond Polymer Refine Red Detection kit (Leica Biosystems, Newcastle, UK). Nuclei were counterstained by haematoxylin, and immunohistochemical stain was carried out by the automatic IHC device (Leica BOND-MAX, Leica Biosystems).

### Statistical analysis

All BM samples were divided into four groups based on duration after transplantation, 16–25, 26–35, 36–45 and 46–55 days (table 2). After immunostaining, all cells, versican-positive cells and CD68-positive cells in a 0.15 mm\(^2\) area of several sections were counted, and the average number and SD of each group were obtained. These data were compared with either each other or those of the age-matched normocellular group (analysis of variance, Bonferroni’s correction). Data of the age-matched poor engraftment group were compared with those from the age-matched and sampling day-matched control (Student’s t test). We used a Stat View program (STAT View for Windows, V5; SAS Institute, Cary, New Castle, USA) and significance was set at p<0.05.

### RESULTS

#### Macrophages are the versican-producing cells in BM

We selected patients who had no haematopoietic or significant systemic diseases for this purpose (table 2, age-matched normocellular group, figure 1A). Results of the single (figure 1B, C) as well as double (figure 1D) IHC on BM clot samples with anti-versican and anti-CD68 antibodies strongly supported the consideration that versican is produced, partially if not entirely, by macrophages residing at the tissue stroma.

#### Kinetics of versican-producing macrophages in repopulating BM after CBSCT

Average numbers and SD of total cells, versican-positive cells and CD68-positive cells at the unit area in clots from the age-matched normocellular group were approximately 221, 6 and 13 cells/0.15 mm\(^2\), respectively (figure 2A–C, dotted horizontal bars). Then, BM clots of patients who underwent CBSCT were stained similarly and the total cells were counted and compared with those of this group (figure 2A–C, closed marks). The total haematopoietic cells in BM after pretreatment and transplantation appeared to be decreased on the +9 day (figure 2A) and recovered in number already for the 16–25 day group. Though not statistically significant, the total cell number kept gradually increasing thereafter (figure 2A). A significant increase in the total cell number was observed for the 46–55 day group compared with the 16–25 day group (*p<0.05). On the contrary, the average number of versican-positive cells increased steeply in the 16–25 group to that of the age-matched normocellular group (**p<0.01, figure 2B), and then sharply decreased (**p<0.01, ***p<0.001, figure 2B) when the total cell number increased. The number of CD68-positive macrophages was unaltered for the first month but fell significantly to the age-matched normocellular group in the 36–45 day group (**p<0.01, figure 2C). The linearly regressed time-course curves of the number of the total and versican-positive cells are schematically shown in figure 2D, demonstrating their inverse relationship over the examined period.

#### Comparison of the poor engraftment group

The total cell number of the BM in the age-matched poor engraftment group was approximately six times less than that of the control (**p<0.001, figure 3A). The number of versican-positive cells appeared to be less than half that of the age-matched and sampling day-matched control, yet it did not reach

---

**Table 1 General conditioning regimen before and after transplantation of our hospital**

<table>
<thead>
<tr>
<th>Day</th>
<th>−7</th>
<th>−6</th>
<th>−5</th>
<th>−4</th>
<th>−3</th>
<th>−2</th>
<th>−1</th>
<th>0</th>
<th>+1</th>
<th>+3</th>
<th>+6</th>
<th>+7</th>
</tr>
</thead>
<tbody>
<tr>
<td>TBI</td>
<td>TBI</td>
<td>CA</td>
<td>CA</td>
<td>CY</td>
<td>CY</td>
<td>Tacrolimus</td>
<td>Transplantation</td>
<td>2.4±0.5×10(^7)/kg</td>
<td>MTX</td>
<td>MTX</td>
<td>MTX</td>
<td>G-CSF</td>
</tr>
</tbody>
</table>

CA, cytarabine; CY, cyclophosphamide; G-CSF, granulocyte-colony stimulating factor; MTX, methotrexate; TBI, total body irradiation.
Table 2 Clinical data of patients enrolled in this study

<table>
<thead>
<tr>
<th>Case no.</th>
<th>Group</th>
<th>Days</th>
<th>Age</th>
<th>Sex</th>
<th>Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Poor</td>
<td>9</td>
<td>58</td>
<td>M</td>
<td>MDS/AML</td>
</tr>
<tr>
<td>2</td>
<td>Poor</td>
<td>20</td>
<td>40</td>
<td>M</td>
<td>AML</td>
</tr>
<tr>
<td>3</td>
<td>Poor</td>
<td>22</td>
<td>59</td>
<td>F</td>
<td>MDS/AML</td>
</tr>
<tr>
<td>4</td>
<td>Poor</td>
<td>23</td>
<td>57</td>
<td>F</td>
<td>AML</td>
</tr>
<tr>
<td>5</td>
<td>Poor</td>
<td>25</td>
<td>34</td>
<td>F</td>
<td>AML</td>
</tr>
<tr>
<td>6</td>
<td>Poor</td>
<td>26</td>
<td>37</td>
<td>M</td>
<td>AML</td>
</tr>
<tr>
<td>7</td>
<td>Poor</td>
<td>28</td>
<td>49</td>
<td>F</td>
<td>AML</td>
</tr>
<tr>
<td>8</td>
<td>Poor</td>
<td>29</td>
<td>43</td>
<td>F</td>
<td>AML</td>
</tr>
<tr>
<td>9</td>
<td>Poor</td>
<td>29</td>
<td>54</td>
<td>M</td>
<td>AML</td>
</tr>
<tr>
<td>10</td>
<td>Poor</td>
<td>33</td>
<td>44</td>
<td>M</td>
<td>AML</td>
</tr>
<tr>
<td>11</td>
<td>Poor</td>
<td>34</td>
<td>55</td>
<td>M</td>
<td>MDS/AML</td>
</tr>
<tr>
<td>12</td>
<td>Poor</td>
<td>36</td>
<td>27</td>
<td>F</td>
<td>AML</td>
</tr>
<tr>
<td>13</td>
<td>Poor</td>
<td>36</td>
<td>55</td>
<td>M</td>
<td>AML</td>
</tr>
<tr>
<td>14</td>
<td>Poor</td>
<td>36</td>
<td>59</td>
<td>M</td>
<td>MDS/AML</td>
</tr>
<tr>
<td>15</td>
<td>Poor</td>
<td>36</td>
<td>60</td>
<td>F</td>
<td>MDS/AML</td>
</tr>
<tr>
<td>16</td>
<td>Poor</td>
<td>38</td>
<td>57</td>
<td>F</td>
<td>AML</td>
</tr>
<tr>
<td>17</td>
<td>Poor</td>
<td>40</td>
<td>54</td>
<td>M</td>
<td>AML</td>
</tr>
<tr>
<td>18</td>
<td>Poor</td>
<td>41</td>
<td>55</td>
<td>F</td>
<td>AML</td>
</tr>
<tr>
<td>19</td>
<td>Poor</td>
<td>42</td>
<td>30</td>
<td>M</td>
<td>AML</td>
</tr>
<tr>
<td>20</td>
<td>Poor</td>
<td>38</td>
<td>3*</td>
<td>50±13†</td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>Poor</td>
<td>46</td>
<td>54</td>
<td>M</td>
<td>AML</td>
</tr>
<tr>
<td>22</td>
<td>Poor</td>
<td>52</td>
<td>40</td>
<td>M</td>
<td>AML</td>
</tr>
<tr>
<td>23</td>
<td>Poor</td>
<td>55</td>
<td>49</td>
<td>F</td>
<td>AML</td>
</tr>
<tr>
<td>24</td>
<td>Poor</td>
<td>55</td>
<td>58</td>
<td>F</td>
<td>AML</td>
</tr>
<tr>
<td>25</td>
<td>Poor</td>
<td>53±2*</td>
<td>50±8†</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Age-matched poor engraftment group

<table>
<thead>
<tr>
<th>Case no.</th>
<th>Group</th>
<th>Days</th>
<th>Age</th>
<th>Sex</th>
<th>Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Poor</td>
<td>20</td>
<td>30</td>
<td>M</td>
<td>AML</td>
</tr>
<tr>
<td>2</td>
<td>Poor</td>
<td>21</td>
<td>31</td>
<td>F</td>
<td>AML</td>
</tr>
<tr>
<td>3</td>
<td>Poor</td>
<td>26</td>
<td>55</td>
<td>M</td>
<td>AML</td>
</tr>
<tr>
<td>4</td>
<td>Poor</td>
<td>34</td>
<td>49</td>
<td>F</td>
<td>AML</td>
</tr>
<tr>
<td>5</td>
<td>Poor</td>
<td>25±6*</td>
<td>41±13†</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Age-matched normocellular group

<table>
<thead>
<tr>
<th>Case no.</th>
<th>Group</th>
<th>Days</th>
<th>Age</th>
<th>Sex</th>
<th>Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Poor</td>
<td>20</td>
<td>20</td>
<td>F</td>
<td>Nephrosis</td>
</tr>
<tr>
<td>2</td>
<td>Poor</td>
<td>27</td>
<td>27</td>
<td>F</td>
<td>Lymphadenitis</td>
</tr>
<tr>
<td>3</td>
<td>Poor</td>
<td>37</td>
<td>37</td>
<td>M</td>
<td>Lymphadenitis</td>
</tr>
<tr>
<td>4</td>
<td>Poor</td>
<td>52</td>
<td>52</td>
<td>M</td>
<td>Hyperthyroidism</td>
</tr>
<tr>
<td>5</td>
<td>Poor</td>
<td>68</td>
<td>68</td>
<td>M</td>
<td>Amyloidosis</td>
</tr>
<tr>
<td>6</td>
<td>Poor</td>
<td>75</td>
<td>75</td>
<td>M</td>
<td>COPD</td>
</tr>
<tr>
<td>7</td>
<td>Poor</td>
<td>86</td>
<td>86</td>
<td>F</td>
<td>Lymphadenitis</td>
</tr>
<tr>
<td>8</td>
<td>Poor</td>
<td>52±2*</td>
<td>52±2*</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Patients were grouped based on the day their clots were sampled. The mean age of each group was not significantly different.

*Indicates the average days and SD after CBSCT in each group. Underlines indicate patients whose bone marrow specimens were obtained multiple times.
†Indicates the average age and SD in each group.
AML, acute myelogenous leukemia; CBSCT, cord blood stem cell transplantation; COPD, chronic obstructive pulmonary disease; days, sampling days; F, female; M, male; MDS/AML, myelodysplastic syndrome overt AML.

Versican is an ECM molecule known to play an important role in cell adhesion, motility and immobilisation of humoral molecules. Moreover, versican participates intimately in the process of human diseases such as inflammation, atherosclerosis, cardiac infarction, and proliferation and invasion of cancer cells. Versican is a significant ECM molecule as mentioned; hence, it is important to determine the type of versican-producing cells that are active at ECM of various normal and diseased tissues.

Several reports demonstrated that monocytes and macrophages, particularly in inflammatory cells, fibroblasts and myofibroblasts express versican. In many normal and disease tissues, however, cells that express versican are still not well established. Moreover, no reports so far have examined the cells in BM, which is known to contain versican. These facts prompted us to delineate cell types that produce versican in BM, while paying particular attention to tissue macrophages (see above). Using the single IHC method, we first stained the normocellular BM and observed that the anti-versican antibody appears to label macrophages. Then, applying double IHC using anti-versican and CD68 antibodies, we stained the same tissues and concluded that the major versican-expressing cells in BM are macrophages.

Macrophages are important players in the process of various diseases such as atherosclerosis, pneumonia, infectious diseases and progression of cancers. Moreover, macrophages are known to play an important role in BM regeneration.33–37 Nevertheless, versican functions as an important scaffold ECM molecule, and the haematopoietic restoration in transplanted BM appears to be regulated by proteoglycans of ECM and humoral factors. Therefore, we hypothesised that macrophage-derived versican may contribute to the regeneration process of BM after SCT for haematopoietic diseases.

Haematopoietic SCTs, BM, PB and CBSCT are performed as treatments for haematolymphoid neoplastic diseases including leukaemias and lymphomas. Clinically, cytarabine (CA) +cyclophosphamide (CY)+total body irradiation (TBI) (CA +CY+TBI) is generally performed in these transplantations as pretreatment to kill neoplastic cells as well as patients’ haematopoietic cells and for the first few weeks, the total cell number in the BM declines. Then, blood SCs from donors are transfused to patients, engrafted and then start to produce progenitors such as neutrophils. They finally appear in PB, increase for 2–3 weeks and reach the normal level after approximately 40 days. An engraftment is defined by the number of neutrophils in the PB, which should be more than 500/μL for three continuous days.

We observed that around 10 days after transplantation the total number of haematopoietic cells in our patients’ BM lowered to the minimum and recovered in number after 3–4 weeks, just as mentioned above. On the contrary, the number of versican-positive macrophages was sharply increased for 4 weeks, just as mentioned above. On the contrary, the number of versican-positive macrophages was sharply increased for 4 weeks, just as mentioned above.
negative/CD68-positive macrophages start to express versican when BM is damaged by preconditioning and SCs are engrafted. In BM of multiple myeloma patients, after allogenic SCT, it becomes rich in chemokines and other humoral factors. Interestingly, versican can activate macrophages to upregulate tumour necrosis factor-α (TNF-α) and interleukin-6 (IL-6). At least, in neuronal cells TNF-α induces versican expression. Perhaps, after preconditioning and CBSCT in BM, a positive feedback loop between versican and macrophage would be in function.

Figure 1  Determination of versican-expressing cells in bone marrow specimens. (A) H&E stain. (B and C) Immunohistochemical stain with anti-versican (B) and anti-CD68 (C) antibodies, respectively, in the same bone marrow tissue. (D) Double immunohistochemical stain with anti-versican together with the anti-CD68 antibodies in bone marrow tissue. The most versican-positive cells (brown colour) are also CD68-positive (red colour) (open arrows). Nuclei were counterstained with haematoxylin. Original magnification for 3A–3D: ×1000.

Figure 2  The average numbers and SD of the total (A), versican-positive (B) and CD68-positive cells (C) in a 0.15 mm² area of bone marrow tissues. The dotted horizontal bars are an average of total, versican-positive and CD68-positive cells from the age-matched normocellular group. (A) *Indicates a significant difference between the 16–25 day and 46–55 day groups (analysis of variance, *p<0.05). Data were linearly well regressed (r²=0.962). (B) ###Indicates a significant difference between the 16 and 25 day and the age-matched normocellular groups (###p<0.001). ** and *** indicate a significant difference between the 16 and 25 day group and other three groups (**p<0.01, ***p<0.001). Linear regression was applied as in (A) (r²=0.282). (C) ## and * indicate a significant difference between the 36 and 45 day group and the age-matched normocellular group (##p<0.01) or 16–25 day group (*p<0.05), respectively. A polynomial curve was well regressed (r²=0.974). (D) A schematic presentation of the versican-positive macrophage (closed line) in reference to the total cells (dotted line). Their corresponding baselines from the age-matched normocellular group were overlaid.

Although the underlying mechanism behind versican’s contribution to BM regeneration is not clear, given that versican serves as a scaffold molecule that binds several serological factors such as chemokines and midkines, it is likely that versican at the BM stroma binds humoral factors such as granulocyte-colony-stimulating factor. In fact, in our hospital and in many others, it is perfused on the +7 day of transplantation.

Another intriguing unsolved question is the origin of macrophages after CBSCT. Given that versican presents a favourable environment in the BM for donors’ SCs, they should not be eliminated by preconditioning. Comparison of BM clots just before and after preconditioning will be essential to determine the hypothesis above. The use of sex-determining in situ hybridisation on the clot specimens of patients who received CBSCT from sex-unmatched donor should also be performed in future.

In this report, we demonstrated that the predominant versican-expressing cells in BM are macrophages, and evaluated a time course of the number of versican-positive macrophages in BM after CBSCT. Our results suggest that versican and/or versican-expressing macrophages have important roles in BM regeneration by establishing a supportive environment at its ECM for transplanted SCs to be engrafted. We are preparing several more cases of AML with CBSCT and will analyse them in the near future. Moreover, in vivo and in vitro experiments on versican induction in macrophages of BM should further be performed to establish the present analysis on human samples.

**Take home messages**

- Versican is produced by macrophages in bone marrow as in many other tissues.
- In bone marrow of patients with acute myelogenous leukaemia after cord blood stem cell transplantation (CBSCT), the number of versican-positive macrophages is inversely correlated to that of total cells.
- Versican seems to play an important role in bone marrow regeneration after CBSCT.

**REFERENCES**


31 Zimmermann DR, Ruoslahti E. Multiple domains of the large fibroblast proteoglycan, versican. EMBO J 1989;8:2975–81.


Kinetics of versican-expressing macrophages in bone marrow after cord blood stem cell transplantation for treatment of acute myelogenous leukaemia

Miho Senda, Ryuichi Fukuyama and Tetsuro Nagasaka

*J Clin Pathol* published online March 7, 2016

Updated information and services can be found at: [http://jcp.bmj.com/content/early/2016/03/07/jclinpath-2015-203496](http://jcp.bmj.com/content/early/2016/03/07/jclinpath-2015-203496)

**Supplementary Material**

Supplementary material can be found at: [http://jcp.bmj.com/content/suppl/2016/03/01/jclinpath-2015-203496.DC1](http://jcp.bmj.com/content/suppl/2016/03/01/jclinpath-2015-203496.DC1)

**References**

This article cites 42 articles, 14 of which you can access for free at: [http://jcp.bmj.com/content/early/2016/03/07/jclinpath-2015-203496#BIBL](http://jcp.bmj.com/content/early/2016/03/07/jclinpath-2015-203496#BIBL)

**Open Access**

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: [http://creativecommons.org/licenses/by-nc/4.0/](http://creativecommons.org/licenses/by-nc/4.0/)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Open access (117)
- Immunology (including allergy) (1664)

**Notes**

To request permissions go to: [http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to: [http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to: [http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)